Cognitive Rehabilitation in People With Metabolic Syndrome and Mild Cognitive Deficits

Sponsor
University of Ioannina (Other)
Overall Status
Recruiting
CT.gov ID
NCT05658354
Collaborator
(none)
50
1
2
25
2

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to investigate the possibility of rehabilitation of mild cognitive deficits in people with metabolic syndrome. We aim to implement a cognitive training program on patients with metabolic syndrome and cognitive deficits, and examine its effectiveness both post-intervention (3 months) and after 12 months.

Researchers will compare two groups, the experimental group that will receive the computerized cognitive training and the control group that will receive no training.

Condition or Disease Intervention/Treatment Phase
  • Other: Computerized cognitive program
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Cognitive Rehabilitation in People With Metabolic Syndrome and Mild Cognitive Deficits
Actual Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Computerized cognitive program

25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia, and perform the computerized cognitive training program (BrainHQ) for 45 minutes per session, twice per week, over the 3-month intervention period.

Other: Computerized cognitive program
BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.

No Intervention: Control group

25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia.

Outcome Measures

Primary Outcome Measures

  1. Change in scores of the Montreal Cognitive Assessment (MoCA) test [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    MoCA is a screening test for mild cognitive dysfunction; range 0-30, higher scores represent better cognitive function

  2. Change in scores of Complex Figure tests [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    Complex Figures assess visuo-constructional ability and visual memory; range 0-36, higher scores represent better cognitive function

  3. Change in scores of Hopkins Verbal Learning Test-Revised (HVLT-R) [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    HVLT-R assesses verbal memory using a list of words; range 0-36 (immediate recall) and range 0-12 (delayed recall), higher scores represent better cognitive function

  4. Change in scores of Digit Span test [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    Digit Span assesses working memory; range 0-14 (performance) and range 2-9 (span) for forward and backward condition, higher scores represent better cognitive function

  5. Change in scores of semantic Verbal Fluency test [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    Verbal Fluency assesses executive function that also relies on language component; higher scores represent better cognitive function

  6. Change in scores of Flanker task [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    Flanker task assesses executive function and inhibition; range 0-48, higher scores represent better cognitive function

  7. Change in scores of Continuous Performance Test (CPT) [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    CPT assesses executive function and inhibition; range 0-100, higher scores represent better cognitive function

  8. Change in scores of Set Shifting [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    Set Shifting assesses executive function and set-shifting; range 0-104, higher scores represent better cognitive function

  9. Change in scores of N-back [baseline, post-intervention (3 months), follow-up (1 year from baseline)]

    N-back assesses working memory; range 0-30, higher scores represent better cognitive function

Secondary Outcome Measures

  1. Change in scores of Everyday Cognition-II (Ecog-II) [baseline, follow-up (1 year from baseline)]

    Ecog-II is a measure of everyday functioning that includes 41 items to assess memory, language, visual, spatial and perceptual abilities, planning, organization, and divided attention; higher scores represent worse everyday functioning

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 years or older

  • Presence of metabolic syndrome according to the criteria of IDF (2005) or revised NCEP-ATP III (2005)

  • Presence of mild cognitive deficit (-1.5 SD below age and education-adjusted normative mean) in previously administered neuropsychological tests of Trail Making test (Part A & B), Verbal Fluency test (animals and letter "x"), Logical Memory test (immediate and delayed recall)

  • Written informed consent to participate

Exclusion Criteria:
  • Presence of any serious neurological or psychiatric condition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina Ioánnina Greece 45110

Sponsors and Collaborators

  • University of Ioannina

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Myrto Koutsonida, PhD candidate, University of Ioannina
ClinicalTrials.gov Identifier:
NCT05658354
Other Study ID Numbers:
  • 27819
First Posted:
Dec 20, 2022
Last Update Posted:
Dec 20, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Myrto Koutsonida, PhD candidate, University of Ioannina
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2022